메뉴 바로가기 본문 바로가기

TEST ITEMS

THE GENERATION DIAGNOSTIC SYSTEM

NT-proBNP

N-terminal pro-brain natriuretic peptide (NT-proBNP) is produced predominately by the cardiac ventricular myocytes[1] and is released in response to myocardial stress and filling pressure[2] and is involved in maintaining intravascular volume homeostasis[3,4]. After stimulation of heart muscle cells, the natriuretic peptides are produced as prohormones (proBNP) and this is cleaved into two fragments which are secreted into the bloodstream as the 32 amino acids active BNP and the N-terminal fragment of 76 amino acids designated as NT-proBNP. NT-proBNP immunoassays are widely used and are now considered to be a useful marker and have a high degree of diagnostic accuracy in clinical practice and cardiovascular research as a diagnostic tool for the occurrence and severity of heart failure (HF)[5,6,7]. Therefore NT-proBNP measurements in human blood are helpful not only for the cardiac disease diagnosis but also for evaluation of patients with suspected HF and assessment of severity of the disease.

References

  • 1. A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab 2001; 47: 265-67
  • 2. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998 May; 135(5 Pt 1):825-32.
  • 3. Pfister R, Schneider CA. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 2004; 349: 25-38.
  • 4. Cowie M.R., Struthers A.D., Wood D.A., Coats A.S., Thompson S.G., PooleWilson P.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997 Nov 8;350(9088):1349-53.
  • 5. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002 Jun 22;324(7352):1498.
  • 6. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, van Veldhuisen DJ. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007 Aug;9(8):787-94. Epub 2007 May 25.
  • 7. Ewald B, Ewald D, Thakkinstian A, Attia J.Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38: 101-13.

AFIAS

Compatible Device AFIAS-1/6
Detection Range 0.1~10 ng/mL
Sample Type Whole Blood,
Serum, Plasma
CV <10%
Comparability 0.997
Reaction Time 15Min

Product News